Home
Mitotech

Mitotech Market Share Analysis for May 2026

mitotech is a biotechnology company with a portfolio of novel mitochondria-targeted small molecules

Industry: N/A

Domainmitotechpharma.com

Year Founded2009

Employees51 - 200

Annual Revenue$10M - $15M

Mitotech

Mitotech (including company regionals)

mitotechpharma.com

See more website traffic and engagement information

Mitotech Revenue up to May 2026 is 10M - 15M

revenue generated by Mitotech top domains

Mitotech top domains revenue over 3 years

Revenue for Mitotech top domains

mitotechpharma.com10M - 15M

See more with Sales Intelligence

Total visits to Mitotech's top domains

Understand Mitotech market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

mitotechpharma.com855

See more with Sales Intelligence

Avg. visit duration in Mitotech's top domains

Analyze Mitotech engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Mitotech's top domains

See how Mitotech keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

mitotechpharma.com1.03

See more with Sales Intelligence

Mitotech top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Mitotech

These are the website technologies, by industry, used by Mitotech top domains

Conversion & Analytics (2)

Google Analytics

Email Services (2)

GoDaddy Email

Mobile (2)

Meta Viewport

Widget (2)

reCAPTCHA

More Technologies

3

See all

News & Signals from Mitotech

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMitotech LLC launches Dry Eye data set supporting SkQ1.Mitotech announces new Dry Eye data set supporting SkQ1's novel mechanism of action.

NewsMitotech LLC launches Plastomitin.Mitotech S.A., a Luxembourg based clinical stage biotechnology company, announced a successful completion of its pre-clinical program and a start of clinical development for systemic drug Plastomitin™ based on Mitotech's lead compound SkQ1.